133 related articles for article (PubMed ID: 20535793)
1. Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics.
Maksymowych WP; Gooch K; Dougados M; Wong RL; Chen N; Kupper H; van der Heijde D
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):826-34. PubMed ID: 20535793
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
Dougados M; Luo MP; Maksymowych WP; Chmiel JJ; Chen N; Wong RL; Davis JC; van der Heijde D;
Arthritis Rheum; 2008 Apr; 59(4):553-60. PubMed ID: 18383418
[TBL] [Abstract][Full Text] [Related]
4. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
Tubach F; Pham T; Skomsvoll JF; Mikkelsen K; Bjørneboe O; Ravaud P; Dougados M; Kvien TK
Arthritis Rheum; 2006 Dec; 55(6):960-3. PubMed ID: 17139643
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis.
Maksymowych WP; Richardson R; Mallon C; van der Heijde D; Boonen A
Arthritis Rheum; 2007 Feb; 57(1):133-9. PubMed ID: 17266072
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
7. Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis.
Rodríguez-Lozano C; Gantes MÁ; González B; Hernández-Beriain JA; Naranjo A; Hernández V; Quevedo-Abeledo JC; Falcón MJ; Machín S; Descalzo MA
J Rheumatol; 2012 Jul; 39(7):1424-32. PubMed ID: 22660807
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
[TBL] [Abstract][Full Text] [Related]
12. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Poddubnyy D; Hermann KG; Callhoff J; Listing J; Sieper J
Ann Rheum Dis; 2014 May; 73(5):817-23. PubMed ID: 24389297
[TBL] [Abstract][Full Text] [Related]
14. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
Inman RD; Maksymowych WP;
J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
[TBL] [Abstract][Full Text] [Related]
17. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.
Maksymowych WP; Rahman P; Shojania K; Olszynski WP; Thomson GT; Ballal S; Wong RL; Inman RD;
J Rheumatol; 2008 Oct; 35(10):2030-7. PubMed ID: 18785308
[TBL] [Abstract][Full Text] [Related]
20. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
